

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): October 29, 2014

PRESSURE BIOSCIENCES, INC.
(Exact name of registrant as specified in its charter)

Massachusetts
(State or other jurisdiction of
incorporation)

000-21615
(Commission
File Number)

04-2652826
(IRS Employer
Identification No.)

14 Norfolk Avenue
South Easton, Massachusetts 02375

(Address of principal executive offices)(Zip Code)

Registrant's telephone number, including area code: (508) 230-1828

N/A
(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
 - Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
 - Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
 - Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
-

Item 8.01 Other Events.

The Company presented at the FSXinterlinked Investor Conference on October 29, 2014. The power point presentation information furnished on Exhibit 99.1 is hereby incorporated by reference under this Item 8.01 as if fully set forth herein.

The information contained in this Current Report, including Exhibit 99.1 are being furnished and not filed pursuant to this Item 8.01 of Form 8-K. Such information shall not be deemed to be “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, and shall not be deemed to be incorporated by reference into any of the Company’s filings under the Securities Act of 1933, as amended, or the Exchange Act whether made before or after the date hereof and regardless of any general incorporation language in such filings, except to the extent expressly set forth by specific reference in such a filing.

Item 9.01 Financial Statements and Exhibits.

- (d) Exhibits

Exhibit

No. Description

99.1 Company information – “Power Point Presentation” dated October 29, 2014 (filed herewith).

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

PRESSURE BIOSCIENCES, INC.

Date: October 31, 2014

By: /s/ Richard T. Schumacher

Richard T. Schumacher
President and Chief Executive Officer

Investor Presentation

Pressure BioSciences, Inc.
(OTCQB: PBIO)

*Discovery Starts
with Sample Preparation™*

FSXinterlinked Investor Conference
Dove Mountain, AZ
October 29-31, 2014

Richard T. Schumacher
President, CEO



Forward Looking Statements

This presentation may contain forward looking statements that reflect management's current views and opinions as to the status of the Company's products, technology and other future events and operations. These statements are neither a promise nor guarantee, but involve risks and uncertainties that could cause actual results to differ materially from those anticipated or indicated. Investors are cautioned that any forward looking statements should be considered in light of such risks and uncertainties including, without limitation, those detailed in the Company's filings with the Securities and Exchange Commission.



Company Overview (OTCQB: PBI)

- 9 FT Staff; Near Boston, MA; Publicly Traded (OTCQB: PBI)
- Market Cap (fully diluted): \$10 Million
- 24 Patents: Pressure Cycling Technology (“PCT”) Platform
- Develop, Mfg, & Sell PCT-based Instruments & Consumables
- Initial Focus in Sample Preparation for the Research Market
- 250 PCT Systems Installed, 150 Customers, 100 Publications
- Early Product Revenue (Q1/Q2):

2012 (\$390K)	2013 (\$418K)	2014 (\$711K)
---------------	---------------	---------------
- New Instrument (HUB880 and Barozyme HT48) and Consumable (micro-Pestle) Releases Will Augment Current Ramping Revenue



Experienced Senior Management & Board

Management


- **Mr. Richard T. Schumacher, President & CEO**
Boston Biomedica (CEO, Founder); Panacos Pharma (President, Co-founder); Trinity Biotech (Founding Group); CBR Labs (Gen' I Mgr) - Harvard Medical School
- **Dr. Edmund Y. Ting, Senior Vice President of Engineering**
Avure Technologies (CSO); Flow Int' l (CSO); Grumman Aerospace; MIT (Ph.D.)
- **Dr. Alexander V. Lazarev, Vice President of R&D**
Proteome Systems; Genomic Solutions; ESA; University of Kazan (Ph.D.)
- **Dr. Nathan P. Lawrence, Vice President of Marketing**
Boston Biomedica; BD; Gene-Trak Systems; Yale University (Ph.D.)
- **Mr. Richard P. Thomley, Chief Financial Officer**
Kiva Systems; SynQor; Catamount Manufacturing; ChemDesign Corp

Board

- | | |
|-----------------------------------|--|
| • Jeffrey Peterson, MS | Chairman |
| • Kevin Pollack, Esq., MBA | Audit Committee Chairman |
| • Vito Mangiardi, MBA | Compensation Committee Chairman |
| • Mickey Urdea, Ph.D. | SAB Chairman |
| • Richard T. Schumacher | |



Primary Sample Preparation for Biomolecular Analysis: Cell Lysis



PBI

Value Proposition: PCT-based biological sample preparation

- Analysis of DNA, RNA, Proteins, & Lipids (“biomolecules”) is Crucial to the Discovery of New Biomarkers
- The Quality of Biomolecule Analysis Depends Significantly on the Quality of the Preparation of the Sample to be Analyzed
- Biological Sample Preparation is a Multi-Billion Market Comprised of an Estimated 500,000 Scientists in 80,000 Research Labs WW
- Current Sample Prep Methods are Highly Inadequate: Bottleneck
- Proven Platform: ~ 250 PCT Systems Installed (~150 Sites)
- Over 100 Publications Highlight the Clear Advantages of the PCT Platform Over Current Competitive Products
- March 2014: Released First-in-Kind Ultra-HP Instrument (100,000 psi)
- June 2014: Released Novel, u-Pestle Consumable for Small Tissue Samples
- **October 2014: Planned Initial Shipments of the New Barozyme HT48 PCT-based System (microwell strips) to Existing Customers and Potential Strategic Partners for High Throughput Sample Preparation (Protein Digestion)**



Biomarker/Forensics Market: Estimated Size

	<u>Estimated Market</u>
• Genomics (DNA/RNA)	\$7.1B in 2015 ^b
• Next Gen Sequencing (DNA)	\$2.7B in 2017 ^c
• Mass Spectrometry (Proteins)	\$2.7B in 2011 ^{a,d}
• Forensic Tools and Products (DNA)	\$17.7B in 2019 ^e
• Sample Prep for all OMICS:	\$8.4B in 2016 ^f
• 500,000 Scientists in 80,000 Biological Research Labs WW ^a	



^a EMMES Group

^b Decisive Bio-Insights

^c Markets & Markets

^d TechNavio

^e Transparency Market Rsh

^f bcc Research

Selected Marquee Customers (150)



HARVARD
MEDICAL SCHOOL



National Institutes
of Health

BIOGEN

STANFORD
UNIVERSITY

MONSANTO



AMGEN



PBI



MERCK



PCT Focus Area: Biomarker Discovery & Forensics

Biomarker Discovery: Cancer, Heart Disease, Stroke, Inf. Diseases, Etc.

Dr. Andreas Huhmer – **Thermo Fisher Scientific**

Dr. Michael Alterman – Tumor Vaccines and Biotechnology Branch, CBER, **FDA**

Dr. Alexander Ivanov – **Harvard School of Public Health**

Dr. Jennifer Van Eyk, **Johns Hopkins School of Medicine**

Dr. Wayne Hubbell, Distinguished Professor, Dept. of Chemistry & Biochemistry, **UCLA**

Dr. Hans Robert Kalbitzer, Professor, **University of Regensburg**

Dr. Ruedi Aebersold, Institute of Molecular Systems Biology, **ETH Zurich**, Switzerland

Forensics: Improved Processing of Rape Kits, Enhanced DNA Detection

Dr. Bruce Budowle, Health Science Center, **University of North Texas**

Dr. Bruce McCord, **Florida International University**


Dr. Dr. Henry C. Lee, **the Henry C. Lee Institute of Forensic Science**



PCT Sample Preparation System



Barocycler™
NEP2320




Barocycler™ NEP3229



PULSE Tube




MicroTubes



PCT-dependent Kits

The Barrier

Automated liquid handling helps ensure accuracy and reproducibility, eliminates repetitive tasks, and frees personnel for other activities.



The Solution (4 years in the making)



June 2014 Release
ASMS Annual Meeting

Initial Shipment
Expected
October 2014

- **Initial Application:**
 - High pressure digestion
- **Consumable:**
 - Proprietary 8-well strips
- **Number of Samples:**
 - 48 samples
- **User Control:**
 - Easy to use touch screen
 - LabView Software

PBI

The Future (is now)



PBI

Professor Wayne L. Hubbell



Prof Wayne Hubbell

- Distinguished Prof: UCLA School of Medicine
- Member, Nat'l Academy of Sciences
- Gold Medal, International EPR Society
- Research: Structure & Function Proteins



Dr. Jennifer Van Eyk

- Prof of Medicine, Cedars-Sinai Med. Ctr.
- Director, Barbara Streisand Women's HC
- Director, NHLBI Prot Innov Ctr, Heart Failure
- Formerly Prof of Medicine, J. Hopkins SoM
- Research: Mechanisms Heart Disease



Mr. David Weild

- Founder, Chairman, CEO: IssuWorks
- Former Vice-Chairman of NASDAQ
- Former Head, Global Equity Trnx, Prud SEC
- Former President, PrudSecurities.com
- Known as "Father of the JOBS Act"

Recent News

- Sept 19th** Completion of the 1st Phase of Barozyme HT48 Commercialization Plan – first install expected in Oct 2014
- Oct 1st** PBI Invited to Speak at Warsaw Stock Exchange. \$100B (US) Available Through Grants. Non-dilutive.
- Oct 20th** Announced Partnership with Powertech Technology Company to Develop China Market for PBI's PCT Platform
- Oct 27th** Breakthrough Method to Permit Quantification of Thousands of Proteins in Needle Biopsy Samples in 12 Hours Presented

Prof. Ruedi Aebersold said: “working with AB SCIEX we developed a new and improved mass spectrometry method called SWATH, which when combined with PCT and consumables (including the u-Pestle) resulted in significantly improved protein data from needle biopsy samples. We believe PCT SWATH will lead to better analysis of needle biopsy samples in both clinical and research settings, leading to advances in personalized medicine, especially cancer diagnosis and treatment.”



Key Investment Highlights

- Pressure Cycling Technology (PCT): Powerful, Enabling, Patented
- Proven Technology: ~ 250 Installations in ~150 Marquee Laboratories
- Experienced Management Team and Board of Directors
- Large Market Opportunity (est. \$6 Billion; 80k Labs)
- Closed \$3M PIPE (Dec 2013 to June 2014): *Fourth Tranche Open to 11/21/14*

Short Term Growth Drivers (2H 2014 into 2015)

- On-going Discussions with Large Potential Strategic Partners
- “Razor/Razorblade” Business Model (Product Rev Up 70% in 1H 2014)
- Possible Spin-off of Vertical Market Applications
- Mfg & Distribution Expansion Outside of the United States (Europe)

- New Products: HUB880 u-Pestle Barozyme HT48

